Posted 6 months ago

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With HR+/​HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

ClinicalTrials.gov ID NCT06312176

Protocol number MK2870-010

Sponsor Merck Sharp & Dohme LLC